{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sjoholm T"],"funding":["Vetenskapsrådet","Uppsala University","Cancerfonden"],"pagination":["76"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9793670"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(1)"],"pubmed_abstract":["Background
To find semi-quantitative and quantitative Positron Emission Tomography/Magnetic Resonance (PET/MR) imaging metrics of both tumor and non-malignant lymphoid tissue (bone marrow and spleen) for Progression Free Survival (PFS) and Overall Survival (OS) prediction in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) undergoing Chimeric Antigen Receptor (CAR) T-cell therapy.Methods
A single-center prospective study of 16 r/r LBCL patients undergoing CD19-targeted CAR T-cell therapy. Whole body 18F-fluorodeoxyglucose (FDG) PET/MR imaging pre-therapy and 3 weeks post-therapy were followed by manual segmentation of tumors and lymphoid tissues. Semi-quantitative and quantitative metrics were extracted, and the metric-wise rate of change (Δ) between pos"],"journal":["Cancer imaging : the official publication of the International Cancer Imaging Society"],"pubmed_title":["Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy."],"pmcid":["PMC9793670"],"funding_grant_id":["2019-01326","2019-01721","20 1303PjF","19 0184Pj"],"pubmed_authors":["Saren T","Lovgren T","Sjoholm T","Korenyushkin A","Enblad G","Loskog A","Kullberg J","Gammelgard G","Ahlstrom H","Essand M"],"additional_accession":[]},"is_claimable":false,"name":"Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.","description":"Background
To find semi-quantitative and quantitative Positron Emission Tomography/Magnetic Resonance (PET/MR) imaging metrics of both tumor and non-malignant lymphoid tissue (bone marrow and spleen) for Progression Free Survival (PFS) and Overall Survival (OS) prediction in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) undergoing Chimeric Antigen Receptor (CAR) T-cell therapy.Methods
A single-center prospective study of 16 r/r LBCL patients undergoing CD19-targeted CAR T-cell therapy. Whole body 18F-fluorodeoxyglucose (FDG) PET/MR imaging pre-therapy and 3 weeks post-therapy were followed by manual segmentation of tumors and lymphoid tissues. Semi-quantitative and quantitative metrics were extracted, and the metric-wise rate of change (Δ) between pos","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-05-10T05:07:58.928Z","creation":"2025-04-06T13:48:58.079Z"},"accession":"S-EPMC9793670","cross_references":{"pubmed":["36575477"],"doi":["10.1186/s40644-022-00513-y"]}}